BIOCON FOUNDER NAMES CLAIRE MAZUMDAR AS SUCCESSOR

Biocon’s founder, Kiran Mazumdar-Shaw has reportedly named her niece, Claire Mazumdar, as her successor. Currently CEO of Bicara Therapeutics, the 37-year-old also drives strategy at Rheos Medicines and serves on the boards of Relay Therapeutics and Noora Health. Her appointment signals continuity and global leadership for Biocon’s future.  

Biocon, India’s pioneering biopharmaceutical company, is preparing for a generational leadership transition as founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor, according to media reports. The move marks a significant moment for the Bengaluru-headquartered firm, which has been synonymous with Kiran’s entrepreneurial vision and global influence in biotechnology.  

Claire Mazumdar, 37, brings a strong international profile to the role. She is currently Chief Executive Officer of Bicara Therapeutics, a clinical-stage biotechnology company focused on developing novel therapies. In addition, she leads business development and corporate strategy at Rheos Medicines, further strengthening her expertise in advancing innovative healthcare solutions.  

Her leadership extends beyond corporate roles, with Claire serving on the Board of Directors of Relay Therapeutics, a company specialising in precision medicine, and Noora Health, a non-profit organisation dedicated to improving healthcare outcomes for families in South Asia. This blend of commercial acumen and social impact underscores her diverse capabilities.  

The succession plan reflects Biocon’s intent to maintain continuity while embracing a global outlook. Kiran Mazumdar-Shaw, widely regarded as one of India’s most influential business leaders, has built Biocon into a multinational enterprise with a strong focus on affordable innovation. By naming Claire, she signals confidence in the next generation’s ability to steer Biocon through evolving challenges in biotechnology and healthcare.  

Claire’s appointment is expected to reinforce Biocon’s strategic ambitions, combining scientific innovation with broader social responsibility. As the company prepares for its next chapter, her leadership could mark a new era of growth, global partnerships, and sustained impact in the life sciences sector.